Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 31 of 81692 for:    measured

FGF21 Can Help Predicting Arterial Stiffness Measured by Cardio-ankle Vascular Index in Renal Transplant Patients (CAVIFGF21)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02704468
Recruitment Status : Completed
First Posted : March 10, 2016
Last Update Posted : July 19, 2016
Sponsor:
Information provided by (Responsible Party):
Thananda Trakarnvanich, Bangkok Metropolitan Administration Medical College and Vajira Hospital

Brief Summary:

Chronic kidney disease(CKD) patients have high incidence of coronary artery problems event after renal transplantation. And remain a major cause of mortality. The major risk marker is arterial stiffness. The cardio-ankle vascular index (CAVI) is a new index of overall stiffness and can estimated the risk of atherosclerosis.

Fibroblast growth factor 21 (FGF-21) is a metabolic regulator that plays important role in cardiac remodeling elevated FGF-21 have been reported in coronary heart disease or carotid artery plaque and could be biomarkers for atherosclerosis disease Investigators aimed to study the association between CAVI and FGF-21 and their relations to various parameters that can contribute to cardiovascular disease eg. homocysteine Echocardiogram findings and other traditional basic factors.


Condition or disease Intervention/treatment
Vascular Stiffness Other: CAVI and FGF-21

Detailed Description:
A total of 90 participants who underwent renal transplant were included in the study. The following measures were done and laboratory data were collected. CAVI, Ecchocariogram, Homocysteine, Hs-CRP, Carotid IMT, FGF-21, Medication after renal transplantation, incidence of cardiovascular disease correlation between categorical data was done by using Pearson's correlation test and multiple regression analysis.

Layout table for study information
Study Type : Observational [Patient Registry]
Actual Enrollment : 100 participants
Time Perspective: Cross-Sectional
Target Follow-Up Duration: 2 Months
Official Title: FGF21 Can Help Predicting Arterial Stiffness Measured by Cardio-ankle Vascular Index in Renal Transplant Patients
Study Start Date : January 2016
Actual Primary Completion Date : July 2016
Actual Study Completion Date : July 2016

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
CAVI and FGF-21
renal transplant patients for more than 1 month measured FGF-21 and CAVI
Other: CAVI and FGF-21
FGf-21 and CAVI was measured in renal transplant patients group and study correlation with arterial stiffness




Primary Outcome Measures :
  1. association between CAVI and FGF-21 with arterial stiffness in renal transplant patients [ Time Frame: 1 month ]
    cross sectional study


Secondary Outcome Measures :
  1. association between Hs-CRP,Homocystein with CAVI [ Time Frame: 1 month ]
    cross sectional study



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
renal transplant pateints for more than 1 month
Criteria

Inclusion Criteria:

  • renal transplant patients patients for more than 1 month

Exclusion Criteria:

  • who had contraindication for CAVI
  • current smoker
  • eGFR <15 ml/min/173
  • cardiac arrthymia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02704468


Locations
Layout table for location information
Thailand
Bangkok metropolitan administraiton of vajira hospital
Bangkok, Thailand, 10170
Sponsors and Collaborators
Bangkok Metropolitan Administration Medical College and Vajira Hospital
Investigators
Layout table for investigator information
Study Director: Thananda Trakarnvanich, M.D. Bangkok metropolitan administration medical college of vajira hospital

Additional Information:

Publications:
KOTANI, K.; REMALEY, A. T. Cardio-AnkleVascular Index (CAVI) and its Potential Clinical Implications for Cardiovascular Disease. CardiolPharmacol, 2013, 2: 108.

Layout table for additonal information
Responsible Party: Thananda Trakarnvanich, Associated Professor, Bangkok Metropolitan Administration Medical College and Vajira Hospital
ClinicalTrials.gov Identifier: NCT02704468     History of Changes
Other Study ID Numbers: 085/58
First Posted: March 10, 2016    Key Record Dates
Last Update Posted: July 19, 2016
Last Verified: July 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Data about CAVI and FGF 21
Keywords provided by Thananda Trakarnvanich, Bangkok Metropolitan Administration Medical College and Vajira Hospital:
CAVI
FGF-21
arterial stiffness
renal transplant